Details of the Drug Combination

General Information of Drug Combination (ID: DCIOPFN)

• Drug Combination Name: Droperidol + Betamethasone
• Indication: Postoperative Vomiting; Status: Phase 3 [1]
• Component Drugs:
  Droperidol (DM0DXA8): Small molecular drug
  Betamethasone (DMAHJEF): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Droperidol

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[2]

Droperidol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Binder	[5]

Droperidol Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
D(2) dopamine receptor (DRD2)	OTBLXKEG	DRD2_HUMAN	Increases ADR	[6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[7]
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Increases ADR	[6]
D(4) dopamine receptor (DRD4)	OTAJTO7N	DRD4_HUMAN	Increases ADR	[6]

Indication(s) of Betamethasone

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency	N.A.	Approved	[3]
Addison disease	5A74.0	Approved	[3]
Allergic rhinitis	CA08.0	Approved	[3]
Angioedema	4A00.15	Approved	[3]
Aspiration pneumonitis	N.A.	Approved	[3]
Autoimmune haemolytic anaemia	3A20	Approved	[3]
Bursitis	N.A.	Approved	[3]
Cerebral edema	8D60.1	Approved	[3]
Congenital adrenal hyperplasia	5A71.01	Approved	[3]
Crohn disease	DD70	Approved	[3]
Dermatitis herpetiformis	EB44	Approved	[3]
Diamond-Blackfan anemia	N.A.	Approved	[3]
Disorder of orbital region	N.A.	Approved	[3]
Epicondylitis	N.A.	Approved	[3]
Erythema multiforme	N.A.	Approved	[3]
Exanthem	N.A.	Approved	[3]
Granuloma annulare	N.A.	Approved	[3]
Inflammation	1A00-CA43.1	Approved	[4]
Inflammatory bowel disease	DD72	Approved	[3]
Miliary tuberculosis	N.A.	Approved	[3]
Multiple sclerosis	8A40	Approved	[3]
Mycosis fungoides	2B01	Approved	[3]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[3]
Psoriasis	EA90	Approved	[3]
Psoriatic arthritis	FA21	Approved	[3]
Rheumatic heart disease	N.A.	Approved	[3]
Sarcoidosis	4B20.5	Approved	[3]
Scalp dermatosis	N.A.	Approved	[3]
Serum sickness	N.A.	Approved	[3]
Severe asthma	CA23	Approved	[3]
Skin disease	EA00-EM0Z	Approved	[3]
Systemic lupus erythematosus	4A40.0	Approved	[3]
Tinea corporis	1F28.Y	Approved	[3]
Tinea cruris	1F28.3	Approved	[3]
Acquired thrombocytopenia	N.A.	Investigative	[3]
Asthma	CA23	Investigative	[3]
Beta-thalassemia major	N.A.	Investigative	[3]
Classic Hodgkin lymphoma	N.A.	Investigative	[3]
Follicular lymphoma	2A80	Investigative	[3]
Rheumatoid arthritis	FA20	Investigative	[3]
Synovitis	N.A.	Investigative	[3]
Tinea pedis	1F28.2	Investigative	[3]
Trichinellosis	N.A.	Investigative	[3]

Betamethasone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Agonist	[9]

Betamethasone Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Betamethasone Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Increases Expression	[11]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Increases Activity	[12]
Mineralocorticoid receptor (NR3C2)	OT0F2V2Z	MCR_HUMAN	Increases Activity	[12]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Increases Expression	[8]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Increases Expression	[8]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[8]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Affects Expression	[13]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Increases Metabolism	[14]

References

• [1] ClinicalTrials.gov (NCT02744495) Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7172).
• [3] Betamethasone FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7061).
• [5] Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):130-40. doi: 10.1016/j.vascn.2006.03.011. Epub 2006 Apr 25.
• [8] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [9] The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83.
• [10] Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
• [11] Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
• [12] Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
• [13] [Steroid drugs and GM-CSF modulates activity of Egr-1 in glioma cells]. Cir Cir. 2013 Jan-Feb;81(1):3-13.
• [14] Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.